$978 Million is the total value of Johnson & Johnson Innovation - JJDC, Inc.'s 21 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 23.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FATE | FATE THERAPEUTICS, INC. | $293,269,000 | +5.3% | 3,379,064 | 0.0% | 29.98% | -16.9% | |
| ARWR | ARROWHEAD PHARMACEUTICALS | $270,065,000 | +24.9% | 3,260,869 | 0.0% | 27.61% | -1.4% | |
| PTGX | PROTAGONIST THERAPEUTICS INC. | $109,919,000 | +73.3% | 2,449,183 | 0.0% | 11.24% | +36.8% | |
| CVRX | New | CVRX, INC. | $97,876,000 | – | 3,495,575 | +100.0% | 10.01% | – |
| LEGN | LEGEND BIOTECH CORPORATIONsponsored ads | $66,878,000 | +41.5% | 1,629,173 | 0.0% | 6.84% | +11.7% | |
| MGTX | MEIRAGTX HOLDINGS PLC | $44,928,000 | +7.4% | 2,898,550 | 0.0% | 4.59% | -15.2% | |
| FUSN | FUSION PHARMACEUTICALS INC. | $29,658,000 | -24.6% | 3,670,516 | 0.0% | 3.03% | -40.5% | |
| VOR | VOR BIOPHARMA, INC. | $20,042,000 | -56.7% | 1,074,658 | 0.0% | 2.05% | -65.8% | |
| PHGE | BIOMX INC. | $11,648,000 | -23.3% | 2,133,402 | 0.0% | 1.19% | -39.5% | |
| RACA | New | THERAPEUTICS ACQUISITION COR | $10,274,000 | – | 1,000,000 | +100.0% | 1.05% | – |
| ACET | ADICET BIO, INC. | $7,501,000 | -21.3% | 728,944 | 0.0% | 0.77% | -37.9% | |
| PHAS | PHASEBIO PHARMACEUTICALS, INC. | $5,978,000 | +7.5% | 1,607,044 | 0.0% | 0.61% | -15.1% | |
| ALDX | ALDEYRA THERAPEUTICS, INC. | $4,473,000 | -4.6% | 394,834 | 0.0% | 0.46% | -24.8% | |
| CSLT | CASTLIGHT HEALTH INC.cl b | $2,134,000 | +74.2% | 811,295 | 0.0% | 0.22% | +37.1% | |
| NPCE | New | NEUROPACE, INC. | $1,319,000 | – | 55,435 | +100.0% | 0.14% | – |
| ZY | New | ZYMERGEN INC. | $662,000 | – | 16,553 | +100.0% | 0.07% | – |
| TCON | TRACON PHARMACEUTICALS, INC. | $545,000 | -21.1% | 84,003 | 0.0% | 0.06% | -37.1% | |
| CBIO | CATALYST BIOSCIENCES, INC. | $290,000 | -13.9% | 66,951 | 0.0% | 0.03% | -31.8% | |
| GRAY | GRAYBUG VISION, INC. | $269,000 | -2.2% | 49,547 | 0.0% | 0.03% | -25.0% | |
| LUNG | PULMONX CORPORATION | $249,000 | -3.5% | 5,639 | 0.0% | 0.02% | -24.2% | |
| SENS | Sell | SENSEONICS HOLDINGS, INC. | $210,000 | -83.8% | 54,621 | -88.9% | 0.02% | -87.5% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | 7 | Q2 2021 | 74.6% |
| PROTAGONIST THERAPEUTICS INC. | 7 | Q2 2021 | 11.2% |
| BIOMX INC. | 7 | Q2 2021 | 8.1% |
| PHASEBIO PHARMACEUTICALS, INC. | 7 | Q2 2021 | 3.5% |
| ALDEYRA THERAPEUTICS, INC. | 7 | Q2 2021 | 1.2% |
| CASTLIGHT HEALTH INC. | 7 | Q2 2021 | 0.4% |
| SENSEONICS HOLDINGS, INC. | 7 | Q2 2021 | 0.2% |
| CATALYST BIOSCIENCES, INC. | 7 | Q2 2021 | 0.2% |
| TRACON PHARMACEUTICALS, INC. | 7 | Q2 2021 | 0.1% |
| MEIRAGTX HOLDINGS PLC | 6 | Q2 2021 | 21.2% |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-04-10 |
| 4 | 2024-03-06 |
| 13F-NT | 2024-02-14 |
| 3/A | 2024-02-02 |
| 4/A | 2024-02-02 |
| SC 13G | 2023-11-16 |
| 13F-NT | 2023-11-09 |
| 3 | 2023-09-18 |
| 3 | 2023-09-18 |
| 4 | 2023-09-18 |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.